Expanding the Role of the Nurse Practitioner in Multiple Sclerosis to Optimize Outcomes: Early Diagnosis, Treatment Advances, and Patient-Centered Care

Released On
May 26, 2021

Expires On
May 26, 2022

Media Type

Completion Time
60 minutes

Neurology, Integrative Medicine, Primary Care, Other

Multiple Sclerosis

Scroll to the Bottom of this Information to Begin this Course

This CME activity is provided by Integrity Continuing Education.

This AANP activity is jointly provided by Global Education Group and Integrity Continuing Education.


This activity is supported by an educational grant from Biogen, Inc.

Credit Available

  • Physician Continuing Education — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurse Practitioner — 1.0 Contact Hour (which includes 0.5 hours of pharmacology) AANP Credit

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational initiative has been designed for nurse practitioners, physician assistants, and physicians who practice in primary care and specialty settings.

Program Overview

Multiple Sclerosis (MS) is a progressive, immune-mediated, neurodegenerative disease that is associated with irreversible physical disability and functional impairment. Due to its heterogeneity, treatment of patients with MS is highly individualized. The availability of disease-modifying therapies (DMTs) has revolutionized the care of patients with MS and currently more than a dozen DMTs are FDA-approved, with several more undergoing late-stage clinical trials. However, with no head-to-head trials of DMTs, nurse practitioners (NPs) are dependent upon national guidelines and educational activities to stay abreast of the safety and efficacy of these agents, along with strategies for optimizing patient outcomes. In their multi-faceted roles of administrators, educators, collaborators, consultants, and advocates, NPs are able to help identify and manage relapses, symptoms, and treatment-related side effects that all can affect the course of the disease.

This educational activity will address these issues by providing NPs an overview of tools to aid in earlier identification of undiagnosed MS or disease relapse, updates on current and emerging DMTs, and strategies to optimize adherence. Application of the knowledge gained will improve outcomes for patients with MS.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Define the role of the NP in the healthcare setting, and their role in the diagnosis and treatment of multiple sclerosis (MS)
  • Describe how to evaluate patients for signs and symptoms of early MS or relapse, to facilitate prompt referral to specialist care
  • Identify available therapies for treatment of MS, and factors to consider in their use in individual patients
  • Characterize strategies to address patient education and adherence challenges, and the long-term monitoring of overall wellness in patients with MS



Patricia K. Coyle, MD

Professor and Vice Chair, Clinical Affairs
Director, MS Comprehensive Care Center
Stony Brook University
Stony Brook, New York


Denise Bruen, ANP-BC, MSN, MSCN

University of Virginia
James Q. Miller Consultative MS Center
Charlottesville, Virginia


Physician Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Credit Designation

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integrity Continuing Education. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour (which includes 0.5 hours of pharmacology).


Disclosures of Conflicts of Interest

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Patricia K. Coyle, MD

  • Consulting Fees : Accordant, Biogen, Bristol-Meyers-Squibb, Celgene, Genzme/Sanofi, GlaxoSmithKline, Janssen, Novartis, Viela Bio
  • Fees for Non-CME/CE Services : Biogen, Janssen
  • Contracted Research : Actelion, Alkermes, Corrana LLC, MedDay, NINDS, Novartis

Denise Bruen, ANP-BC, MSN, MSCN

  • Consulting Fees : Biogen, Viela Bio, Novartis, EMD Serono, Genentech/Roche, Genzyme, Janssen

The planners and managers, Michelle R. Rizzo, ELS, and Donna Fausak, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months. The Global Education Group planners and managers, Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, and Ashley Cann, also have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of May 26, 2021 through May 26, 2022, participants must:

  • Read the learning objectives and faculty disclosures.
  • Complete the pretest.
  • Study the educational activity.
  • Complete the posttest and the evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education and Global Education Group do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Contact Information

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

For information about AANP accreditation of this activity, please contact Global Education Group at (303) 395-1782 or cme@globaleducationgroup.com.